Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

s certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should" and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through March 31, 2011, it incurred net losses and negative cash flows from operating activities of approximately $60.0 million and $47.0 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseea
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
    (Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
    (Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
    Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
    ... Feb. 24, 2011 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... of $20.9 million for the fourth quarter ended December ... for the fourth quarter of 2009, and revenues of ...
    ... N.J. and EMERYVILLE, Calif., Feb. 24, 2011 ... ONXX ) today announced the companies ... randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets ... versus placebo plus capecitabine for the treatment of ...
    Cached Medicine Technology:HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 2HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 3HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 4HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 5HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7
    (Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
    (Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
    (Date:7/9/2014)... is one of the most important organs in the ... utilize our food properly this is its synthesis ... our organism this is its detoxification function. Lack ... food all damage the liver. The resulting diseased cells ... and life-threatening liver failure. According to the German Liver ...
    (Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
    (Date:7/8/2014)... Calif. The Department of Defense,s Defense Advanced ... Laboratory (LLNL) up to $2.5 million to develop ... record and stimulate neurons within the brain to ... , The research builds on the understanding that ... certain regions of the brain encode information, store ...
    Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
    ... confirms previous studies showing that a high-protein diet can ... carbohydrate diet. Researchers have also demonstrated that when both ... diet is still more effective at reducing body fat. ... effect when a protein-rich diet is combined with exercise ...
    ... extract adult stem cells from adipose or fatty tissues ... ,International scientists will announce findings from a significant number ... tissue could eventually be used to treat injured or ... the third annual International Fat Applied Technology Society conference, ...
    ... is none which is not a poison; the right ... 1538 ,Breathlessness can have a major impact on ... //Despite the best efforts of scientists for many years, ... to deal with the sensation of breathlessness without suppressing ...
    ... remains, may be at the root of bovine spongiform ... the latest issue of The Lancet had forwarded this ... case or cases of BSE is currently unknown. Sheep ... (TSE) that arose spontaneously has long been considered as ...
    ... men got their share from women in the inheritance of cancer ... breast and ovarian cancers also significantly increases the danger of some ... ,Genetic mechanisms have been examined in the familial inheritance of ... is associated with increased risk in women who have a family ...
    ... urging countries to intensify surveillance and prepare for emergencies due ... countries to Europe, Middle East and Africa.// Though the initial ... chances of the virus may mutate and may cause infections ... dangerous and requires immediate control and elimination of the virus ...
    Cached Medicine News:Health News:A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss 2Health News:Adult Stem Cells From Fat Tissues For Healing 2Health News:Mad Cow Disease Has Roots Traceable To Man 2Health News:Genes responsible for cancer in women associated with increased cancer risk in men 2
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: